Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.
Press Releases
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
March 8, 2021
BASKING RIDGE, N.J. (March 8, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed […]
Read MoreCaladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 3, 2021
BASKING RIDGE, N.J. (March 3, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed […]
Read MoreCaladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 25, 2021
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development […]
Read MoreCaladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time
February 18, 2021
BASKING RIDGE, N.J. (February 18, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular […]
Read MoreCaladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
February 17, 2021
BASKING RIDGE, N.J. (February 17, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular […]
Read MoreCaladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
February 12, 2021
BASKING RIDGE, N.J. (February 12, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular […]
Read MoreCaladrius Biosciences Closes $25.0 Million Private Placement
January 25, 2021
Caladrius Biosciences Closes $25.0 Million Private Placement BASKING RIDGE, N.J. (January 25, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical […]
Read MoreCaladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021
January 25, 2021
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021 BASKING RIDGE, N.J. (January 25, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences Announces $25.0 Million Private Placement
January 21, 2021
Caladrius Biosciences Announces $25.0 Million Private Placement BASKING RIDGE, N.J. (January 21, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company […]
Read MoreCaladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
January 19, 2021
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Initiation of the Phase 2b FREEDOM […]
Read MoreCaladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021
January 6, 2021
Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021 BASKING RIDGE, N.J. (January 6, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update
December 14, 2020
Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Program strategy and prioritization supports projection of available capital through 2021 BASKING RIDGE, N.J. (December 14, 2020) – […]
Read MoreCaladrius Biosciences to Webcast Live at Life Sciences Investor Forum
December 10, 2020
Caladrius Biosciences to Webcast Live at the Life Sciences Investor Forum Company invites individual and institutional investors, as well as advisors and analysts, to attend […]
Read MoreCaladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference
December 9, 2020
Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference BASKING RIDGE, N.J. (December 9, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer
November 17, 2020
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING […]
Read MoreCaladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020
November 10, 2020
Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020 BASKING RIDGE, N.J. (November 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results
November 5, 2020
Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. […]
Read MoreCaladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November
November 4, 2020
Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November BASKING RIDGE, N.J. (November 4, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors
November 2, 2020
Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors BASKING RIDGE, N.J. (November 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call
October 29, 2020
Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (October 29, […]
Read More